Pharmacological activation of M1R has been pursued as a therapeutic approach in Alzheimer’s disease and schizophrenia, where M1R-selective agonists such as xanomeline and GSK1034702 have demonstrated pro-cognitive and antipsychotic effects by modulating cortical acetylcholine-dependent signaling [123]. Here, CHRM1 is linked to early-onset autosomal dominant Alzheimer disease.